VENTANA PD-L1 SP142 Rabbit Monoclonal Antibody OptiView PD-L1 SP142
2 OptiView PD-L1 SP142 OptiView PD-L1 SP142 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 PD-L1 OptiView PD-L1 SP142 TC IC PD-L1 SP142 OptiView DAB OptiView Rabbit Monoclonal IHC antibody developed by Spring Bioscience Corporation Fully Automated With specific and robust signal Highly Reproducible Accurate scoring and educational resources
OptiView PD-L1 SP142 3 PD-L1 PD-L1 1 B7-H1 CD274 45-55kDaCD274 PD-11 T 1 PD-L1 PD-1 B7-1 T 2 PD-L1ADC 3 PD-L1 PD-1 T 11 10 79.3% 31% 18% NSCLC80 85% 40% 5, 6 30 7 NSCLC NSCLC 5 4.7 8 NSCLC B PD-L1 腫瘍浸潤免疫細胞 PD-L1 が PD-1 受容体に結合することにより T 細胞が不活化される PD-1 は PD-L1 と PD-L2 の両方に結合する PD-1 PD-1 PD-L2 PD-L1 PD-L1 腫瘍浸潤免疫細胞上の PD-L1 は 活性化 T 細胞の抑制を引き起こすことができる B7-1 (CD80) T 細胞 TCR T 細胞受容体 (TCR) への MHC 抗原複合体の結合は T 細胞シグナル伝達を誘発する PD-1 MHC B7-1 (CD80) PD-L1 PD-L1 は T 細胞表面上の B7-1 および PD-1 受容体と結合する PD-L1 腫瘍細胞 腫瘍細胞は免疫介在性の異物排除機構から逃れるために PD-L1 の発現を増加させる 腫瘍細胞上の PD-L1 発現は 発癌シグナルによって発現が増加される
4 OptiView PD-L1 SP142 好酸球 顆粒球 肥満細胞 B 細胞 マクロファージ 細胞傷害性 T 細胞 制御性 T 細胞 樹状細胞 骨髄由来免疫抑制細胞 NK 細胞 血小板 腫瘍細胞 ベンタナ OptiView PD-L1(SP142) による染色で免疫細胞の PD-L1 発現の多様性が強調されます 大部分はリンパ球 マクロファージ 樹状細胞および顆粒球です 血管内皮細胞 周皮細胞 線維芽細胞 TME TME T 9,10 TMEPD-L1 PD-1/PD-L1 PD-L1 TPD-1 B7-1 11 T PD-1 B7-1 PD-L1 T PD-L1 PD-L1
OptiView PD-L1 SP142 5 OptiView PD-L1 SP142 OptiView PD-L1 SP142 23000EZX00005000 518-114329 741-4860 PD-L1 SP142 RxDx 50 518-111182 790-4795 250 518-111427 760-700 OptiView DAB 250 518-113742 760-099 OptiView 50 ULTRA, XT, GX ULTRA VENTANA PDL1 SP142 XT VENTANA PDL1 SP142 GX VENTANA PDL1 SP142 Baking Antibody Counterstain Post Counterstain VENTANA PD-L1 SP142 Negative Control Hematoxylin 4 min Bluing Reagent 4 min OptiView PD-L1 SP142 OptiView PD-L1 SP142 PD-L1
6 OptiView PD-L1 SP142 OptiView PD-L1 SP142 OptiView PD-L1 SP142 1TC 2 IC OptiView PD-L1 SP142TC IC TC IC PD-L1 1 TC20 2 IC20 1 PD-L1 PD-L1TC PD-L1 50% PD-L1 5% 50% PD-L1 1% 5% PD-L1 PD-L1 1% PD-L1IC PD-L1 10% PD-L1 5% 10% PD-L1 1% 5% PD-L1 PD-L1 1% TC3 TC2 TC1 TC0 IC3 IC2 IC1 IC0 TC IC TC IC HE TC IC 3 4 TC IC 3 TC IC 20 4 TC IC 20 IC TC HE TC IC IC TC
OptiView PD-L1 SP142 7 References 1. Blank, C and Mackensen, A, Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother, 2007. 56 5 : p.739-745. 2. Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1costimulatory molecule to inhibit T cell responses. Immunity. 2007;27 1 :111-122. 3. Dong H, Zhu G, Tamada K, Chen L. B7-H1, a third member of the B7 family, co-stimulates T-cell proliferation and interleukin-10 secretion. Nat Med. 1999;5 12 :1365-1369. 4. Herbst RS, Soria JC, Kowanetz M, et al. Predictive correlates of response to the anti-pd-l1 antibody MPDL3280A in cancer patients. Nature. 2014;515 7528 :563-567. 5., ganjoho.jp, 2012 6., zangankyo.ncc.go.jp, 2017 7. Siegel R, Naishadham D, Jemal A. Cancer Statistics, 2013. CA Cancer J Clin. 2013;63 1 :11-30. 8. Howlader N, Noone AM, Krapcho M,et al. eds. SEER Cancer Statistics Review CSR,1975-2012. National Cancer Institute. http://seer.cancer.gov/csr/1975_2012/. Published 2015-04-23. Updated 2015-11-18. Accessed 2016-02-08. 9. NCI Dictionary of Cancer Terms. Tumor microenvironment. http://www.cancer.gov/publications/dictionaries/cancer-terms?cdrid=561725 10. AACR. The Function of Tumor Microenvironment in Cancer Progression. http://www.aacr.org/meetings/pages/meetingdetail.aspx?eventitemid=73#.v6pcfpkrkae 11. Blank, C and Mackensen, A, Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion. Cancer Immunol Immunother, 2007. 56 5 : p.739-745.
108-0075 東京都港区港南 1-2-70 http://www.roche-diagnostics.jp カスタマーソリューションセンター 0120-600-152 VENTANA は ロシュ社の登録商標です 1085.TD.TMS.3000.PAB01-026A